RICHARD S. STEIN, M.D.; HARVEY M. GOLOMB, M.D.; CHARLES H. DIGGS, M.D.; PETER MAUCH, M.D.; SAMUEL HELLMAN, M.D.; PETER H. WIERNIK, M.D.; JOHN E. ULTMANN, M.D.; DAVID S. ROSENTHAL, M.D.
The clinical significance of anatomic substage was assessed in 130 patients with Hodgkin's disease in pathologic stage III-A: stage III-A includes involvement of spleen, or splenic, celiac, or portal nodes, or any combination of these; stage III-A includes involvement of para-aortic, iliac, or mesenteric nodes, with or without upper abdominal involvement. Median follow-up was 58 months. Both 5-year disease-free survival, 74% versus 46%, and 5-year survival, 94% versus 65%, were better (P < 0.001) in stage III-A than in stage III2-A. In stage III,-A, 5-year disease-free survival was better in patients receiving radiotherapy and chemotherapy than in patients receiving radiotherapy alone as initial treatment, 96% versus 63%, P < 0.003; however, 5-year survival rates in these treatment groups were similar, 100% versus 91%, P = 0.22. For stage III2-A, both 5-year disease-free survival, 76% versus 32%, P < 0.001, and 5-year survival, 84% versus 56%, P < 0.03, were superior with radiotherapy-chemotherapy. Consideration of anatomic substage may aid therapeutic planning for stage III Hodgkin's disease.
STEIN RS, GOLOMB HM, DIGGS CH, MAUCH P, HELLMAN S, WIERNIK PH, et al. Anatomic Substages of Stage III-A Hodgkin's Disease: A Collaborative Study. Ann Intern Med. ;92:159–165. doi: 10.7326/0003-4819-92-2-159
Download citation file:
Published: Ann Intern Med. 1980;92(2_Part_1):159-165.
Results provided by:
Copyright © 2018 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use